[go: up one dir, main page]

WO2007013845A1 - Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution - Google Patents

Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution Download PDF

Info

Publication number
WO2007013845A1
WO2007013845A1 PCT/SE2006/000900 SE2006000900W WO2007013845A1 WO 2007013845 A1 WO2007013845 A1 WO 2007013845A1 SE 2006000900 W SE2006000900 W SE 2006000900W WO 2007013845 A1 WO2007013845 A1 WO 2007013845A1
Authority
WO
WIPO (PCT)
Prior art keywords
stroke
evolution
compound
benzene
methyl
Prior art date
Application number
PCT/SE2006/000900
Other languages
French (fr)
Inventor
Hans-Göran HÅRDEMARK
Larry Rodichok
Sunita Sheth
Warren Wasiewski
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of WO2007013845A1 publication Critical patent/WO2007013845A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a novel method for the treatment or prophylaxis of stroke- in-evolution.
  • the invention relates to the use of disodium 4-[(tert ⁇ butylimino)methyl]benzene-l,3-disulfonate acid N-oxide [ ⁇ -(2,4-disulfophenyl)-N- tert- butylnitrone disodium salt] for the treatment or prophylaxis of stroke-in-evolution.
  • U.S. patent 5,488,145 discloses the compound ⁇ -(2,4-disulfo ⁇ henyl)-iV-tert-butyhiitrone and pharmaceutically acceptable salts thereof.
  • U.S. patent 5,475,032 discloses the use of such compounds in the treatment of stroke and of progressive central nervous system function loss conditions.
  • U.S. patent 5,508,305 discloses the use of such compounds for ameliorating the side effects caused by oxidative damage resulting from antineoplastic disease treatment. Similar disclosures are also made in WO 95/17876.
  • U.S. patent 5,780,510 discloses the use of these same compounds in the treatment of concussion.
  • a method of treating stroke-in- evolution which comprises administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
  • Salts of compounds of formula (I) may be formed by reacting the free acid or another salt thereof, with two or more equivalents of an appropriate base, using methods that are well known in the art.
  • the salts of compounds of formulae (I) will normally be those formed with pharmaceutically acceptable cations.
  • the cation may be a monovalent material such as sodium, potassium, lithium, ammonium, alkylammonium or diethanolammonium.
  • it may be a polyvalent cation such as calcium, magnesium, aluminium or zinc.
  • It may also be a mixed salt formed with a polyvalent cation such as calcium or magnesium in combination with a pharmaceutically acceptable anion such as halide (for example chloride), phosphate, sulphate, acetate, citrate or tartrate.
  • the compound of formula (I) is the disodium salt of formula (II).
  • the invention provides a method of treating stroke-in-evolution which comprises administering an effective amount of a compound of formula (II) to a patient in need thereof.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment or prophylaxis of stroke-in-evolution. In another aspect, the invention provides a compound of formula (II) for use in the treatment or prophylaxis of stroke-in-evolution.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment or prophylaxis of stroke-in-evolution.
  • the invention provides the use of a compound of formula (II) in the manufacture of a medicament for use in the treatment or prophylaxis of stroke-in- evolution.
  • therapy also includes prophylaxis unless there are specific indications to the contrary.
  • Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
  • Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
  • Stroke is caused by an interruption of blood flow to a portion of the brain. This is most often due to a blockage within an artery causing an ischemic stroke. Such strokes account for about 88% of all strokes.
  • the most common cause of an ischemic stroke is intrinsic narrowing of an artery to the brain due to a combination of atherosclerosis (accumulation of fatty materials plus secondary inflammation) culminating in the formation of a blood clot in the narrowed area.
  • the obstruction is due to a blood clot (embolus) originating elsewhere, especially the heart or a major blood vessel supplying the brain, that dislodges and travels to the brain to block a smaller artery within the brain itself.
  • About 12% of all strokes are caused by rupture of a blood vessel within the brain, called an intracerebral haemorrhage, or over the surface of the brain, called a subarachnoid haemorrhage.
  • Stroke is an acute event.
  • the phrase "stroke-in-evolution" is used to describe a specific condition in which an initial stroke appears to progress steadily from onset. This progression may be related to progressive brain oedema. Patients who suffer stroke-in- evolution are likely to develop more serious disabilities. Death is also a more frequent consequence. There is currently no approved medication for stroke-in-evolution.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound or salt thereof (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • a pharmaceutically acceptable adjuvant diluent or carrier.
  • Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
  • compositions of this invention may be adm ⁇ iistered in standard manner for the disease or condition that it is desired to treat. Suitable methods will be readily apparent to the man skilled in the art. Parenteral administration, particularly intravenous administration, is preferred. The administration may involve the use of a bolus dose or doses and /or infusion.
  • the dosage administered will, of course, vary with the mode of administration, the treatment desired and the severity of the condition or disorder to be treated. Such parameters will normally be decided by the attending physician.
  • the pharmaceutical composition may also contain, or be co-administered (simultaneously or sequentially) with, one or more other pharmacological agents of value in conjunction with stroke-in-evolution.
  • Disodium 4-[(fer ⁇ butylimino)methyl]benzene- 1 ,3-disulfonate acid N-oxide concentrate solution for infusion 400 mg/ml; 20 ml vial) (WO 01/89507) was diluted in 500 ml of physiologic (9 mg/ml) saline to a final concentration of approximately 15 mg/ml.
  • a loading dose of 151 ml (2270 mg) of the diluted solution was administered over the first hour and was followed by a maintenance dose adjusted for the patient's creatinine clearance (Clcrea - a measure of kidney function). The maintenance infusion was continued for another 71 hours.
  • the maintenance doses adjusted for creatinine clearance were as follows:
  • Stroke-in-evolution occurred in only 6.5% of the 858 patients who received disodium 4- [(ter/-butylimino)methyl]benzene-l,3-disulfonate acid N.-oxide. In comparison, stroke-in- evolution occurred in 8.1% of 847 patients who received placebo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the treatment or prophylaxis of stroke-in-evolution is disclosed.

Description

Use of 4- [ (tert-butylimino) methyl] benzene-l,3-disulfonate N- oxide against stroke-in-evolution
Field of the Invention
The present invention relates to a novel method for the treatment or prophylaxis of stroke- in-evolution. In particular, the invention relates to the use of disodium 4-[(tert~ butylimino)methyl]benzene-l,3-disulfonate acid N-oxide [α-(2,4-disulfophenyl)-N- tert- butylnitrone disodium salt] for the treatment or prophylaxis of stroke-in-evolution.
Background of the Invention U.S. patent 5,488,145 discloses the compound α-(2,4-disulfoρhenyl)-iV-tert-butyhiitrone and pharmaceutically acceptable salts thereof. U.S. patent 5,475,032 discloses the use of such compounds in the treatment of stroke and of progressive central nervous system function loss conditions. U.S. patent 5,508,305 discloses the use of such compounds for ameliorating the side effects caused by oxidative damage resulting from antineoplastic disease treatment. Similar disclosures are also made in WO 95/17876. U.S. patent 5,780,510 discloses the use of these same compounds in the treatment of concussion.
We have now surprisingly discovered that 4-[(tert-butylimino)methyl]benzene-l,3- disulfonic acid Ν-oxide and pharmaceutically acceptable salts thereof are useful as a novel method for the treatment or prophylaxis of the condition known as stroke-in-evolution.
Disclosure of the Invention
In accordance with the present invention, there is provided a method of treating stroke-in- evolution which comprises administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
Figure imgf000002_0001
Salts of compounds of formula (I) may be formed by reacting the free acid or another salt thereof, with two or more equivalents of an appropriate base, using methods that are well known in the art.
The salts of compounds of formulae (I) will normally be those formed with pharmaceutically acceptable cations. The cation may be a monovalent material such as sodium, potassium, lithium, ammonium, alkylammonium or diethanolammonium. Alternatively, it may be a polyvalent cation such as calcium, magnesium, aluminium or zinc. It may also be a mixed salt formed with a polyvalent cation such as calcium or magnesium in combination with a pharmaceutically acceptable anion such as halide (for example chloride), phosphate, sulphate, acetate, citrate or tartrate.
In one embodiment, the compound of formula (I) is the disodium salt of formula (II).
Figure imgf000003_0001
In another aspect, the invention provides a method of treating stroke-in-evolution which comprises administering an effective amount of a compound of formula (II) to a patient in need thereof.
In another aspect, the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment or prophylaxis of stroke-in-evolution. In another aspect, the invention provides a compound of formula (II) for use in the treatment or prophylaxis of stroke-in-evolution.
In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment or prophylaxis of stroke-in-evolution.
In another aspect, the invention provides the use of a compound of formula (II) in the manufacture of a medicament for use in the treatment or prophylaxis of stroke-in- evolution.
In the context of the present specification, the term therapy also includes prophylaxis unless there are specific indications to the contrary.
Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
Processes for the manufacture of compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed in WO 01/51460 and WO 01/51461.
Stroke is caused by an interruption of blood flow to a portion of the brain. This is most often due to a blockage within an artery causing an ischemic stroke. Such strokes account for about 88% of all strokes. The most common cause of an ischemic stroke is intrinsic narrowing of an artery to the brain due to a combination of atherosclerosis (accumulation of fatty materials plus secondary inflammation) culminating in the formation of a blood clot in the narrowed area. In about 30% of strokes the obstruction is due to a blood clot (embolus) originating elsewhere, especially the heart or a major blood vessel supplying the brain, that dislodges and travels to the brain to block a smaller artery within the brain itself. About 12% of all strokes are caused by rupture of a blood vessel within the brain, called an intracerebral haemorrhage, or over the surface of the brain, called a subarachnoid haemorrhage.
Stroke is an acute event. The phrase "stroke-in-evolution" is used to describe a specific condition in which an initial stroke appears to progress steadily from onset. This progression may be related to progressive brain oedema. Patients who suffer stroke-in- evolution are likely to develop more serious disabilities. Death is also a more frequent consequence. There is currently no approved medication for stroke-in-evolution.
We have now surprisingly established that 4-[(tert-burylimino)methyl]benzene-l,3- disulfonic acid N-oxide (I) and pharmaceutically acceptable salts thereof, particularly the disodium salt (II) are useful as a novel method for the treatment or prophylaxis of stroke- in-evolution.
The compounds of formula (I) and pharmaceutically acceptable salts thereof will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound or salt thereof (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
Specific formulations of pharmaceutically acceptable salts of a compound of formula (I), particularly formulations of a compound of formula (II), suitable for parenteral administration are disclosed in WO 01/89507.
The pharmaceutical compositions of this invention may be admύiistered in standard manner for the disease or condition that it is desired to treat. Suitable methods will be readily apparent to the man skilled in the art. Parenteral administration, particularly intravenous administration, is preferred. The administration may involve the use of a bolus dose or doses and /or infusion.
For the treatment of stroke-in-evolution, the dosage administered will, of course, vary with the mode of administration, the treatment desired and the severity of the condition or disorder to be treated. Such parameters will normally be decided by the attending physician.
In addition to the compound of the present invention, the pharmaceutical composition may also contain, or be co-administered (simultaneously or sequentially) with, one or more other pharmacological agents of value in conjunction with stroke-in-evolution.
Examples Patients treated within 6 h of suffering an acute ischaemic stroke were randomised to receive either an intravenous bolus dose of disodium 4-[(tert-butylimino)methyl]benzene- 1,3-disulfonate acid N-oxide over 1 h and then a continued infusion over the next 71 h, or matching placebo, in addition to standard care.
Disodium 4-[(fer^butylimino)methyl]benzene- 1 ,3-disulfonate acid N-oxide concentrate solution for infusion (400 mg/ml; 20 ml vial) (WO 01/89507) was diluted in 500 ml of physiologic (9 mg/ml) saline to a final concentration of approximately 15 mg/ml. A loading dose of 151 ml (2270 mg) of the diluted solution was administered over the first hour and was followed by a maintenance dose adjusted for the patient's creatinine clearance (Clcrea - a measure of kidney function). The maintenance infusion was continued for another 71 hours. The maintenance doses adjusted for creatinine clearance were as follows:
Figure imgf000007_0001
Patients were formally assessed at enrolment, at 24 and 72 hours after enrolment, and at 7, 30 and 90 days.
Stroke-in-evolution occurred in only 6.5% of the 858 patients who received disodium 4- [(ter/-butylimino)methyl]benzene-l,3-disulfonate acid N.-oxide. In comparison, stroke-in- evolution occurred in 8.1% of 847 patients who received placebo.
During the administration of disodium 4-[(ter?-butylimino)methyl]benzene-l ,3-disulfonate acidN-oxide, stroke-in-evolution occurred in only 6.2% of patients, whilst it occurred in 7.0% of patients during the infusion of placebo.
These data clearly demonstrate the efficacy of disodium 4-[(tert- butylimino)methyl]benzene- 1 ,3 -disulfonate acid N-oxide in significantly treating the condition known as stroke-in-evolution.

Claims

C L A I M S
1. A method of treating stroke-in-evolution which comprises administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof.
Figure imgf000008_0001
2. A method according to Claim 1 wherein the compound is disodium 4-[(tert- butylimino)methyl]benzene-l,3-disulfonate acid N-oxide.
3. A method according to either Claim 1 or Claim 2 wherein the stroke-in-evolution develops following an acute ischaemic stroke.
4. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment or prophylaxis of stroke-in- evolution.
5. The use of a compound of formula (II) in the manufacture of a medicament for use in the treatment or prophylaxis of stroke-in-evolution.
PCT/SE2006/000900 2005-07-26 2006-07-20 Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution WO2007013845A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70266505P 2005-07-26 2005-07-26
US60/702,665 2005-07-26

Publications (1)

Publication Number Publication Date
WO2007013845A1 true WO2007013845A1 (en) 2007-02-01

Family

ID=37683652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2006/000900 WO2007013845A1 (en) 2005-07-26 2006-07-20 Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution

Country Status (1)

Country Link
WO (1) WO2007013845A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103301099A (en) * 2012-03-06 2013-09-18 江苏先声药物研究有限公司 Composition of 2,4-disulfonylalpha-phenyl-tert-butyl-nitrone and 2-camphenol

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREEN A.R.: "Protecting the brain: the search for a clinically effective neuroprotective drug for stroke", CRITICAL REVIEWS IN NEUROBIOLOGY, vol. 16, no. 1&2, 2004, pages 91 - 97, XP003004214 *
MAPLES K.R. ET AL.: "Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke", CNS DRUGS, vol. 18, no. 15, 2004, pages 1071 - 1084, XP003004213 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103301099A (en) * 2012-03-06 2013-09-18 江苏先声药物研究有限公司 Composition of 2,4-disulfonylalpha-phenyl-tert-butyl-nitrone and 2-camphenol
CN103301099B (en) * 2012-03-06 2016-12-14 江苏先声药业有限公司 2,4 disulfonyl α Phenyl t-butyl Nitrone and the compositionss of 2 baras camphors

Similar Documents

Publication Publication Date Title
JP2024160001A (en) Drug therapy for the prevention or treatment of glaucoma
JP5522877B2 (en) Moxifloxacin / sodium chloride preparation
JP6353577B2 (en) Combination composition
AU2011281035A1 (en) Acetycysteine compositions and methods of use thereof
BR112019012299A2 (en) pharmaceutical formulations for the treatment of glaucoma and methods for the manufacture and use thereof
CN110974828A (en) Application of compound Axitinib in preparation of medicine for treating cerebrovascular diseases and pharmaceutical composition of compound Axitinib
WO2006104086A1 (en) Therapeutic agent for thrombosis
WO2007013845A1 (en) Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against stroke-in-evolution
WO2012005605A1 (en) A combination composition comprising ibuprofen and paracetamol
TW201500042A (en) Treatment of hypotension associated with hemodialysis
JP5791064B2 (en) Pharmaceutical composition
WO2007013844A1 (en) Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea
AU2001225625A1 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
WO2007013843A1 (en) Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia
JP2022001606A (en) Aqueous composition containing epinastine or a salt thereof
WO2007013842A1 (en) Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
WO2007013841A1 (en) Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema
JPWO2006004028A1 (en) Quinolone-containing pharmaceutical composition
WO2021185842A1 (en) Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
US20220218627A1 (en) Intranasal administration of ketamine to cluster headache patients
EP1485084B9 (en) Use of an l-ascorbic acid salt to prepare a pharmaceutical composition for ophthalmic topical use capable of improving the level of l-ascorbic acid in the eye
JPS63502270A (en) Ophthalmic pharmaceutical composition having mydriatic effect
EP3730137A1 (en) Therapeutic agent for glaucoma comprising fp agonist and blocker
WO2022122010A1 (en) Application of jak inhibitor in kidney disease
EP3493849A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06758082

Country of ref document: EP

Kind code of ref document: A1